Esto es del dia 14 pasado, lo he visto ahora.
3. Threshold Pharmaceuticals (Nasdaq: THLD)
View gallery
.
I have been following this biotech firm for several years, acknowledging all the while that investors would need to show patience during the long and arduous phases of clinical trial testing.
Well, the wait is almost over.
Threshold's TH-302, which focuses on oxygen-deprived tumors that are hard to treat with traditional chemotherapy drugs. Though the company is testing a wide range of tumors in Phase I and II clinical trials, it is also conducting Phase III trials for soft tissue sarcoma and pancreatic cancer.
The primary data collection phase for the soft tissue sarcoma trial nearing completion (ClinicalTrials.gov says it was scheduled to be completed in June). Although Threshold won't provide a complete set of analysis to the FDA until next winter, it is expected to release a preliminary look at the data in coming months.
Positive results could send this stock far higher, in part because it would serve as an endorsement for all of the TH-302 earlier-stage trials.
[More from StreetAuthority.com: 6 Stocks With Major Insider Buying]
Risks to Consider: Even armed with solid clinical trial data, some drugs just don't pass muster with the FDA, so no drug is a sure thing, until it is approved.
Action to Take --> Biotech and medtech catalysts often stare investors right in the face, yet still get ignored. I greatly prefer focusing on companies with drugs or devices in Phase II or Phase III trials, simply because earlier-stage trials often end up yielding poor results. These three stocks are poised to deliver solid catalysts in 2014, making this a good time to listen to their imminent quarterly conference calls.
http://finance.yahoo.com/news/3-health-care-stocks-primed-150000250.html
Finalizado el Periodo de Suscripción Preferente, la Entidad Agente,
en su caso, determinara si hay acciones sobrantes por suscribir, y se
abrirá, entonces, el Periodo de Asignación Discrecional a fin de su
distribución en las condiciones que se establecerán.
A tal efecto, la Entidad Agente lo pondrá en conocimiento del
Consejo de Administración de la Sociedad no más tarde del día hábil
siguiente a la finalización del Período de Suscripción Preferente y se
iniciará el Período de Asignación Discrecional.
El Período de Asignación Discrecional tendrá una duración de
quince días hábiles desde que la Entidad Agente se lo comunique al 22
Consejo de Administración según lo previsto en el párrafo anterior.
Durante este período los Accionistas e Inversores podrán cursar
peticiones de suscripción de acciones sobrantes ante la Entidad
Agente. Las peticiones de suscripción realizadas durante este
Período de Asignación Discrecional serán firmes, incondicionales e
irrevocables, a salvo la facultad del Consejo de decidir su
adjudicación.
A la finalización de dicho período la Entidad Agente comunicará las
peticiones cursadas por los Inversores al Consejo de Administración
de la Sociedad. El Consejo de Administración decidirá
discrecionalmente la distribución de acciones a favor de los
Inversores
En un informe de ciencias de la vida, George Zavoico nos habla de NVAX y THLD entre otras farmas.
http://www.thelifesciencesreport.com/pub/na/shining-a-light-on-overlooked-and-underfollowed-biotechs-george-zavoico
Saludos